Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + Lenalidomide + Rituximab in Treatment-naive FL and MZL
NCT06792825Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2025
- Primary completion
- Jul 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by Masonic Cancer Center. Started Aug 2025; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06792825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792825.